Ligand Pharmaceuticals Income Statement
View: Annual | Quarterly
| Dec 08 | Dec 07 | Dec 06 | |
|---|---|---|---|
| Revenue | 27.3 | 12.9 | 141.0 |
| Cost of Goods Sold | 0.0 | -- | 22.6 |
| Gross Profit | -- | -- | 118.3 |
| Gross Profit Margin | 0.0% | 0.0% | 83.9% |
| SG&A Expense | 23.8 | 30.4 | 79.7 |
| Depreciation & Amortization | 1.1 | 1.7 | 15.4 |
| Operating Income | (97.3) | (52.7) | (163.7) |
| Operating Margin | -- | -- | -- |
| Nonoperating Income | (2.2) | (1.2) | 1.3 |
| Nonoperating Expenses | 2.0 | -- | -- |
| Income Before Taxes | (97.5) | (53.5) | (174.3) |
| Income Taxes | (0.1) | (18.7) | (38.4) |
| Net Income After Taxes | (97.5) | (34.8) | (135.9) |
| Continuing Operations | (97.5) | (34.8) | (135.9) |
| Discontinued Operations | (0.7) | 316.4 | 104.1 |
| Total Operations | (98.1) | 281.7 | (31.7) |
| Total Net Income | (98.1) | 281.7 | (31.7) |
| Net Profit Margin | -- | 2,184.6% | -- |
| Diluted EPS from Total Net Income ($) | (1.03) | 2.87 | (0.39) |
| Dividends per Share | 0.00 | 0.00 | 0.00 |
© 2009 Morningstar, Inc. Financial Data provided by
